

Published in final edited form as:

*Res Microbiol.* 2013 September ; 164(7): 689–694. doi:10.1016/j.resmic.2013.05.001.

## Genetic characterization of *moaB* mutants of *Escherichia coli*

Stanislav G. Kozmin and Roel M. Schaaper\*

Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA

Stanislav G. Kozmin: stanislav.kozmin@duke.edu

### Abstract

The *moaABCDE* operon of *Escherichia coli* encodes enzymes essential for the biosynthesis of the molybdenum cofactor (Moco). However, the role of the *moaB* gene within this operon has remained enigmatic. Here, we have investigated the effect of *moaB* defects on two phenotypes diagnostic for Moco-deficiency: chlorate-resistance and sensitivity to the base analog 6-*N*-hydroxylaminopurine (HAP). We found that transposon insertions in *moaB* caused partial Moco-deficiency associated with chlorate-resistance, but not for HAP-sensitivity. On the other hand, in-frame deletions of *moaB*, or *moaB* overexpression, had no effect on either phenotype. Our combined data are consistent with the lack of any role for MoaB in Moco biosynthesis in *E. coli*.

### Keywords

Molybdenum cofactor; *moaABCDE* operon; *mogA* gene; 6-*N*-hydroxylaminopurine; Chlorate resistance

## 1. Introduction

Molybdenum cofactor (Moco) is an essential prosthetic group for the activity of a range of pro- and eukaryotic oxidoreductases (Schwarz et al., 2009). In its simplest form, Moco is a pterine derivative, named molybdopterin or metal-binding pterin (MPT), that contains a molybdenum atom coordinated by a dithiolene group (Mo-MPT). Biosynthesis of the Moco is an evolutionary conserved, multistep process, which has been studied in detail (Schwarz et al., 2009) (Fig. 1A). The first step is conversion of GTP to a cyclic pyranopterin monophosphate (cPMP), performed in *E. coli* by the *moaA* and *moaC* gene products. In the second step, the dithiolene group is introduced into cPMP by the *moaD*, *moaE*, and *moeB* gene products, yielding MPT. Finally, the molybdenum atom is inserted onto the dithiolene sulphurs *via* an MPT-AMP intermediate synthesized by the *mogA* gene product. This intermediate is then converted to Mo-MPT by the *moeA* gene product. Mo-MPT can be further modified by the *mobA* gene product to yield a molybdopterin guanine dinucleotide form (MGD). The MGD form is utilized by at least ten *E. coli* molybdoenzymes, including three nitrate reductases, three formate dehydrogenases, two trimethylamine-*N*-oxide reductases, dimethyl sulfoxide reductase, and biotin sulfoxide oxidoreductase (Iobbi-Nivol and Leimkühler, 2012). Thus far, five *mobA*-independent molybdoactivities have also been described in *E. coli*, including PaoABC aldehyde oxidoreductase and XdhABC xanthine

\*Corresponding author: Tel.: 919-541-4250; Fax: 919-541-7613, schaaper@niehs.nih.gov (Roel M. Schaaper).

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

oxidase (which both use molybdopterin cytosine dinucleotide), YedY *S(N)*-oxide reductase (which utilizes Mo-MPT), and two 6-*N*-hydroxylaminopurine (HAP)-reductases, YcbX and YiiM (for which the precise form of Moco unknown) (Iobbi-Nivol and Leimkühler, 2012; Kozmin and Schaaper, 2007; Kozmin et al., 2008).

The *moaABCDE* operon (Fig. 1B) is the largest operon involved in Moco biosynthesis *E. coli*. As noted above, it contains the genes essential for the first (*moaA*, *moaC*) and the second (*moaD*, *moaE*) steps of Moco biosynthesis. However, the role of the *moaB* gene in this operon has remained enigmatic (Magalon and Mendel, 2008). All known Moco-deficient *E. coli* mutants display a common phenotype - resistance to chlorate under anaerobic conditions, which is due to lack of nitrate reductase activity responsible for conversion of chlorate to toxic chlorite (Stewart and MacGregor, 1982). However, no chlorate-resistant (*chl*) mutants in the *moaB* gene have ever been isolated (Magalon and Mendel, 2008; Shanmugam et al., 1992). In the present work, we have investigated the effect of several *moaB* defects using two established markers of Moco deficiency in *E. coli*: chlorate resistance and sensitivity to the base analog 6-*N*-hydroxylaminopurine (HAP) (Kozmin et al., 2000; Kozmin and Schaaper, 2007). HAP sensitivity is due primarily to the lack of two Moco-dependent activities, YcbX and YiiM, which mediate the conversion of toxic HAP to non-toxic adenine (Kozmin et al., 2008). A minor role in HAP detoxification is also played by a third molybdoenzyme, biotin sulfoxide oxidoreductase (BisC) (Kozmin et al., 2008). Our results, using precise in-frame deletions of the individual genes of the *moaABCDE* operon, indicate that *moaB* is fully dispensable for both Moco-dependent phenotypes and that, hence, MoaB is not required for Moco biosynthesis.

## 2. Materials and Methods

### 2.1. Media and chemicals

Bacteria were cultivated in LB broth (Miller, 1972) or minimal Vogel-Bonner medium (VB) (Vogel and Bonner, 1956) containing 0.2 % glucose as carbon source and supplemented with 1 µg/ml of thiamine. Solid media contained 1.5% agar. For selection of antibiotic-resistant clones, media were supplemented with 35 µg/ml of kanamycin, 15 µg/ml of tetracycline, or 100 µg/ml of ampicillin. 6-*N*-hydroxylaminopurine (HAP) was purchased from Midwest Research Institute (Kansas City, USA). All other chemicals were from Sigma-Aldrich.

### 2.2. Bacterial strains and plasmids

The *E. coli* strains used in this study are listed in Table 1, along with their source or derivation. In-frame deletion alleles of *moaA-E* genes were generated using a PCR-mediated one-step gene-replacement procedure (Datsenko and Wanner, 2000). In each case, the PCR primers contained 50-nt extensions complementary to the left or right end of the gene as well as 20-nt 3'-ends complementary to the kanamycin-resistance ( $Kan^r$ ) module of plasmid pKD13 (Datsenko and Wanner, 2000), generating kanamycin-resistant deletion/insertions. Initial deletions were made in strain NR17368 (Table 1). After elimination of the  $Kan^r$  markers using plasmid pCP20 (Datsenko and Wanner, 2000), the markerless in-frame deletions were verified by DNA sequencing. In this manner, each gene of the *moa* operon was deleted precisely from start to stop codon, as exemplified in Fig. 1B for the *moaB* deletion. Finally, the deletions were transferred into strains NR10836 and KP7600 by P1 transduction using the closely-linked *zbi-29:Tn10* insertion [17.7 min (Nichols et al., 1998)] as a selective (tetracycline-resistance) marker (Table 1). Transfer of each *moa* deletion was verified by PCR. To obtain MoaB- overexpressing constructs, *moaB* gene was amplified from strain NR10836 (Table 1) using primers moaB-SacI (5'-cta gag ctc aat gag tca ggt aag cac tga a-3') and moaB-BamHI (5'-ata ggg atc cat ggg tca gtt gcg aca tac-3') or moaB-NdeI

(5'-cta cca tat gag tca ggt aag cac tga a-3'), and cloned into the SacI/BamHI site of a multicopy plasmid pBluescript II SK(+) (Stratagene), or into the NdeI/BamHI site of the pET3a expression vector (Novagen).

### 2.3. Spot-test for HAP-sensitivity

Stationary *E. coli* cultures grown in LB were diluted 30-fold in 0.9% NaCl and transferred to VB plates using a multi-prong replicator device (approximately 0.1 ml total per plate) (Kozmin et al. 2000). After the spots had dried, 5 microliters of a 10-mg/ml solution of HAP in dimethyl sulfoxide were spotted onto the center of the plate. The plates were incubated overnight at 37 °C and inspected the next day for zones of inhibition.

### 2.4. Test for chlorate sensitivity

Approximately  $10^3$  cells were plated on LB plates containing various concentrations of  $\text{KClO}_3$ . The plates were incubated for 48 h at 37° C under anaerobic conditions using a Becton Dickinson BBL gas pack anaerobic system.

## 3. Results and Discussion

### 3.1. A split phenotype for *moaB* transposon insertions

Our investigation into the role of *moaB* was triggered by an initial observation of a “split” phenotype for two *moaB*::mini-Tn10 mutants (JD26194 and JD26195) obtained from the National Institute of Genetics of Japan (see Table 1). These JD strains are part of a genome-wide collection of mini-Tn10(*lacZa-kan*)-mediated gene knockouts (Miki et al., 2008). Other strains from this collection carrying insertions in the *moaA*, *moaC*, *moaD*, and *moaE* genes were, as expected, both HAP-sensitive and chlorate-resistant (Table 2). In contrast, the two *moaB*::mini-Tn10(*lacZa-kan*) JD26194 and JD26195 (they differ in orientation of the mini-Tn10 insert, see Fig. 1) were fully HAP-resistant indicating normal status of the YcbX/YiiM enzymes, but were resistant to 15 mM potassium chlorate [the standard concentration used for selection of *chl* mutants (Miller 1972; Stewart and MacGregor, 1982)], indicating an impairment of nitrate reductase activity (Table 2). Thus, the strains exhibited a split phenotype.

To further investigate the phenotypes, we transferred the two *moaB*::mini-Tn10 alleles by P1 transduction into the NR10836 strain background, which has been used routinely in our laboratory to investigate the effects of Moco deficiencies (Kozmin et al., 2000). As shown in Table 2, the NR10836 *moaB*::mini-Tn10 derivatives were, again, HAP resistant, but a different result was obtained for chlorate resistance. The strains were sensitive to 15 mM potassium chlorate, while resistant to the 5 mM and 0.5 mM chlorate concentrations (Table 2). Note that 5 mM chlorate is sufficient to kill essentially 100% of the cells of the parental NR10836 strain (see Fig. 1C), while on 0.5 mM chlorate plates very small colonies are seen, which may be termed “chlorate-inhibited” (see Stewart and MacGregor, 1982) (Table 2). Thus, two conclusions are apparent: (i) the *moaB*::mini-Tn10 insertions provide an observable level of chlorate resistance, and (ii) the *moaB*::mini-Tn10 derivatives of the JD series are resistant to higher chlorate concentrations than those of the NR10836 background. This latter difference between the two strain sets is likely a background-specific issue. Indeed, the parent to the JD strains, KP7600, was chlorate resistant up to 5 mM chlorate (Table 2). This elevated basal level of resistance may be due to some uncharacterized mutation affecting nitrate reductase activity in KP7600. This is likely specific to KP7600, because its parental strain, W3110, displayed a pattern of chlorate-sensitivity similar to NR10836 (data not shown).

### 3.2. Lack of phenotype for in-frame *moaB* deletion

Regardless of the strain background difference, an explanation was sought that could account for the split phenotype of the *moaB*::mini-Tn10 insertions: an increased level of chlorate-resistance along with unaltered HAP-sensitivity. Two possibilities were considered. The Tn10 insertions in *moaB* could have a polar effect on expression of the downstream *moaCDE* genes, leading to a reduction of the total Moco level in the cell. Such reduction might have a more pronounced effect on chlorate-sensitivity than it has on HAP sensitivity. Alternatively, the *moaB* defects could specifically reduce the level of MGD, which is required for the nitrate reductase activities, but would not affect the level of Mo-MPT, required for the *moaA*-independent YcbX and YiiM activities (Kozmin and Schaaper, 2007; Kozmin et al., 2008). To test these proposals, we constructed an in-frame deletion allele of *moaB* (along with in-frame deletions of the other genes of the operon, see Materials and Methods). As expected, in-frame deletions of the *moaA*, *moaC*, *moaD*, and *moaE* genes led to clear HAP-sensitivity and chlorate-resistance (Fig. 1C and Table 2). The strains carrying the in-frame *moaB* deletion were resistant to HAP (Fig. 1C and Table 2), and yielded a pattern of chlorate-sensitivity that was indistinguishable from that of the respective parental strains, NR10836 or KP7600 (Fig. 1C and Table 2). Thus, while the NR10836 and KP7600 backgrounds have an intrinsic difference in chlorate sensitivity, the *moaB* deletion does not further affect this intrinsic sensitivity and, hence, *moaB* does not confer a split-phenotype. These results argue against any significant role of MoaB in Moco biosynthesis.

We also constructed a  $\Delta moaB \Delta ycbX \Delta yiiM$  triple mutant and observed that it did not display any altered HAP-sensitivity compared to the  $\Delta ycbX \Delta yiiM$  double mutant (data not shown). As the  $\Delta ycbX \Delta yiiM$  strain still carries some level of HAP resistance due to BisC activity (Kozmin et al., 2008), we conclude that, in addition, the BisC biotin sulfoxide reductase activity is also independent of *moaB*.

### 3.3. Possible polar effects of the *moaB*::mini-Tn10 insertions

As the *moaB* gene resides in the middle of the *moaABCDE* operon, it seems plausible to assume that the increased chlorate-resistance of the *moaB*::mini-Tn10 insertion mutants, accounting for the split phenotype, is due to a polar effect of the transposon insertions on the downstream *moaCDE* genes, leading to at least a partial Moco deficiency. While we have not pursued this, gene expression measurements may be used to confirm this effect directly. It is an interesting question why a partial Moco deficiency would have a stronger effect on chlorate resistance than on HAP-sensitivity. It is possible that the presumed impairment of cofactor biosynthesis restricts the availability of MGD (for nitrate reductase) more severely than that of Mo-MPT (for YcbX and YiiM). On the other hand, the effect may simply reflect the relative sensitivity of the two phenotypic assays used: a given level of Moco deficiency may lead to a reduction in nitrate reductase activity sufficient for a demonstrable level of chlorate resistance, whereas a more drastic reduction in HAP-detoxification would be needed to confer HAP-sensitivity. Another interesting case of Moco limitation was reported for a molybdopterin synthase sulfurylase mutant (*moeB*<sup>A228T</sup>), which was able to produce an essentially normal level of active nitrate reductase (NarGHI) but little or no active DMSO reductase (DmsABC) (Sambasivarao et al., 2002). As both reductases use the same (Mo-bisMGD) cofactor, the differential sensitivity to Moco limitation was ascribed to a much greater affinity of NarGHI for the cofactor, allowing it to more effectively scavenge the available cofactor pool (Sambasivarao et al., 2002).

A recent study in *E. coli* described a novel tellurate reductase activity, which was reportedly molybdopterin-dependent (Theisen et al., 2013). The activity was dependent on the *moaA* and *moaB* genes, but, interestingly, not on the *moaC* or *moaD* genes (Theisen et al., 2013). The strains used were of the Keio collection (Baba et al., 2006), and carry a kanamycin

resistance cassette in each inactivated gene. Hence, a polar effect of the *moaB* insertion is to be expected. However, the apparent lack of effect of the *moaC* and *moaD* deletions remains to be investigated as the MoaC and MoaD proteins are known to be essential for molybdopterin biosynthesis (Iobbi-Nivol and Leimkühler, 2012; Schwarz et al., 2009).

### 3.4. Physiological role of MoaB?

Having demonstrated that there is no obvious role for the *moaB* gene product in the investigated molybdoactivities, the question still remains what is the possible physiological role for MoaB in *E. coli*. Both the primary sequence and crystal structure of MoaB show strong similarities with the MogA protein (Bader et al., 2004; Bevers et al., 2008; Sanishvili et al., 2004), which catalyzes formation of the MPT-AMP intermediate during the Mo-insertion step into Moco. Indeed, in the archaeon *Pyrococcus furiosus*, which lacks a MogA protein, its MoaB enzyme is responsible for the MPT adenylylation (Bevers et al., 2008). However, the *E. coli* MoaB protein, in contrast to the *P. furiosus* MoaB, was shown incapable of forming the MPT-AMP intermediate (Bevers et al., 2008). The fact that *E. coli mogA* mutants display clear Moco-deficiency associated phenotypes (Kozmin and Schaaper, 2007; Shanmugam et al., 1992) also indicates that the chromosomal copy of *moaB* cannot substitute for the lack of *mogA*. In addition, the loss of nitrate reductase activity in *mogA*-deficient *E. coli* could not be restored by overexpression of MoaB protein (Bevers et al., 2008). Likewise, we did not detect any change in HAP- or chlorate-sensitivity in the  $\Delta mogA$  strains carrying *moaB*-overexpressing vectors (Table 2), clearly indicating that MoaB cannot substitute for MogA. Based on the ability of MoaB protein to bind GTP and, presumably, other intermediates of Moco biosynthesis (Sanishvili et al., 2004), it has been proposed that MoaB may play a yet unknown regulatory role in the Moco biosynthesis pathway, for example, by sensing the Moco status in cell (Bevers et al., 2008) or functioning as a Moco transporting/storage protein (Sanishvili et al., 2004). It has also been proposed that MoaB and MogA might form functional hetero-oligomers (Sanishvili et al., 2004). However, if such oligomers occur, their lack (as in the *moaB* mutant) does not appear to have major consequences, at least for the molybdoactivities tested here. Also, MoaB overproduction in an otherwise wild-type strain did not show any negative consequences (see Table 2), which might have resulted if such hetero-oligomers would be involved in a mechanism for MoaB-mediated regulation of Moco biosynthesis.

As demonstrated by Bevers and coworkers, residue D56 in *P. furiosus* MoaB is essential for its catalytic activity (Bevers et al., 2008). As *E. coli* MoaB contains a Glu residue (E52) at the corresponding position, this could be a reason for its inactive state. Sequence comparisons revealed several other amino acid substitutions in *E. coli* MoaB (as well as in several other *Enterobacteriaceae* species that have both a MogA and MoaB protein), such as those corresponding to *P. furiosus* MoaB residues D57, R87 and T90, which could also be responsible for the inactivate state of *E. coli* MoaB (Bevers et al., 2008). On the other hand, we have noted the presence of potentially active MoaB proteins in several *Serratia* species (YP\_004499735.1; ZP\_06641453.1; YP\_001477553.1; ZP\_06189083.1), because they retain the four D, D, R, and T residues at the positions homologous to D56, D57, R87, and T90 of *P. furiosus* MoaB. These species also express potentially active MogA proteins (data not shown), thus weakening the perceived connection between the active status of MoaB and the absence of MogA. Interestingly, an alignment of the *moa* operons among *Enterobacteriaceae* genomes in the EcoCyc database ([www.ecocyc.org](http://www.ecocyc.org)) (Keseler et al., 2011) shows the specific absence of *moaB* from the *moa* operon (*moaACDE*) in several genera, including *Edwardsiella*, *Photorhabdus*, *Proteus*, *Providencia*, *Xenorhabdus*, and *Yersinia* (all of which also have a *mogA* gene) (data not shown). Based on these observations, one might speculate that *moaB* is the more ancient gene in *Enterobacteriaceae*; *mogA* may have arisen later by *moaB* duplication or horizontal gene transfer. Possibly,

MogA had certain evolutionary advantages over MoaB leading to accumulation of deleterious mutations in *moaB* in certain species (as in *E. coli*) or to a complete loss of *moaB* in others (see above).


## Acknowledgments

We thank Drs. K. Chan and M. Itsko of the NIEHS for their helpful comments on the manuscript for this paper. This work was supported by project ES050170 of the Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS).

## References

- Baba T, Ara T, Hasegawa M, Takao Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol.* 2006; 2:20060008.10.1038/MSB4100050
- Bader G, Gomez-Ortiz M, Haussmann C, Bacher A, Huber R, Fischer M. Structure of the molybdenum-cofactor biosynthesis protein MoaB of *Escherichia coli*. *Acta Crystallogr D Biol Crystallogr.* 2004; 60:1068–1075. [PubMed: 15159566]
- Bevers LE, Hagedoorn PL, Santamaria-Araujo JA, Magalon A, Hagen WR, Schwarz G. Function of MoaB proteins in the biosynthesis of the molybdenum and tungsten cofactors. *Biochemistry.* 2008; 47:949–956. [PubMed: 18154309]
- Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA.* 2000; 97:6640–6645. [PubMed: 10829079]
- Iobbi-Nivol C, Leimkühler S. Molybdenum enzymes, their maturation and molybdenum cofactor biosynthesis in *Escherichia coli*. *Biochim Biophys Acta.* 2012;10.1016/j.bbabi.2012.11.007
- Keseler IM, Collado-Vides J, Santos-Zavaleta A, Peralta-Gil M, Gama-Castro S, Muñoz-Rascado L, Bonavides-Martinez C, Paley S, Krummenacker M, Altman T, Kaipa P, Spaulding A, Pacheco J, Latendresse M, Fulcher C, Sarker M, Shearer AG, Mackie A, Paulsen I, Gunsalus RP, Karp PD. EcoCyc: a comprehensive database of *Escherichia coli* biology. *Nucleic Acids Res.* 2011; 39 (Database issue):D583–D590. [PubMed: 21097882]
- Kozmin SG, Pavlov YI, Dunn RL, Schaaper RM. Hypersensitivity of *Escherichia coli*  $\Delta(uvrB-bio)$  mutants to 6-hydroxylaminopurine and other base analogs is due to a defect in molybdenum cofactor biosynthesis. *J Bacteriol.* 2000; 182:3361–3367. [PubMed: 10852865]
- Kozmin SG, Schaaper RM. Molybdenum cofactor-dependent resistance to *N*-hydroxylated base analogs in *E. coli* is independent of MobA function. *Mutat Res.* 2007; 619:9–15. [PubMed: 17349664]
- Kozmin SG, Leroy P, Pavlov YI, Schaaper RM. *YcbX* and *yjiM*, two novel determinants for resistance of *Escherichia coli* to *N*-hydroxylated base analogues. *Mol Microbiol.* 2008; 68:51–65. [PubMed: 18312271]
- Magalon, A.; Mendel, RR. Chapter 3.6.3.13, Biosynthesis and insertion of the Molybdenum Cofactor. In: Böck, A.; Curtiss, R., III; Kaper, JB.; Karp, PD.; Neidhardt, FC.; Nyström, T.; Slauch, JM.; Squires, CL.; Ussery, D., editors. *EcoSal - Escherichia coli and Salmonella: Cellular and Molecular Biology*. ASM Press; Washington, DC: Jan 18. 2008 posting date <http://www.ecosal.org>
- Miki T, Yamamoto Y, Matsuda H. A novel, simple, high-throughput method for isolation of genome-wide transposon insertion mutants of *Escherichia coli* K-12. *Methods Mol Biol.* 2008; 416:195–204. [PubMed: 18392969]
- Miller, JH. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory; Cold Spring Harbor, New York: 1972.
- Nichols BP, Shafiq O, Meiners V. Sequence analysis of Tn10 insertion sites in a collection of *Escherichia coli* strains used for genetic mapping and strain construction. *J Bacteriol.* 1998; 180:6408–6411. [PubMed: 9829956]
- Sambasivarao D, Turner RJ, Bilous PT, Rothery RA, Shaw G, Weiner JH. Differential effects of a molybdopterin synthase sulfurylase (*moeB*) mutation on *Escherichia coli* molybdoenzyme maturation. *Biochem Cell Biol.* 2002; 80:435–443. [PubMed: 12234097]

- Sanishvili R, Beasley S, Skarina T, Glesne D, Joachimiak A, Edwards A, Savchenko A. The crystal structure of *Escherichia coli* MoaB suggests a probable role in molybdenum cofactor synthesis. *J Biol Chem.* 2004; 279:42139–42146. [PubMed: 15269205]
- Schwarz G, Mendel RR, Ribbe MW. Molybdenum cofactors, enzymes and pathways. *Nature.* 2009; 460:839–847. [PubMed: 19675644]
- Shanmugam KT, Stewart V, Gunsalus RP, Boxer DH, Cole JA, Chippaux M, DeMoss JA, Giordano G, Lin EC, Rajagopalan KV. Proposed nomenclature for the genes involved in molybdenum metabolism in *Escherichia coli* and *Salmonella typhimurium*. *Mol Microbiol.* 1992; 6:3452–3454. [PubMed: 1484496]
- Singer M, Baker TA, Schnitzler G, Deischel SM, Goel M, Dove W, Jaacks KJ, Grossman AD, Erickson JW, Gross CA. A collection of strains containing genetically linked alternating antibiotic resistance elements for genetic mapping of *Escherichia coli*. *Microbiol Rev.* 1989; 53:1–24. [PubMed: 2540407]
- Stewart V, MacGregor CH. Nitrate reductase in *Escherichia coli* K-12: involvement of *chlC*, *chlE*, and *chlG* loci. *J Bacteriol.* 1982; 151:788–799. [PubMed: 7047497]
- Theisen J, Zylstra GJ, Yee N. Genetic evidence for a molybdopterin-containing tellurate reductase. *Appl Environ Microbiol.* 2013; 79:3171–3175. [PubMed: 23475618]
- Vogel HJ, Bonner DM. Acetylmornithinase of *Escherichia coli*: partial purification and some properties. *J Biol Chem.* 1956; 218:97–106. [PubMed: 13278318]



**Fig. 1.** Effect of in-frame deletions of the individual genes of the *E. coli moaABCDE* operon on Moco-dependent activities. A. Steps in Moco biosynthesis and the responsible genes (Schwarz et al., 2009). B. Organization of the *moaABCDE* operon. Indicated are the locations of the *moaB*::mini-Tn10(*lacZα-kan*) insertions as present in strains JD26194 and JD26195, as well as the endpoints of the *moaB* deletion showing the ATG start and TAA stop codon as well as the remaining in-frame “scar” of 28 residues (see Materials and methods). All other *moa* genes were deleted in identical manner. C. HAP- or chlorate-sensitivity of the in-frame deletion mutants (NR17378 - NR17382) and the wild-type strain (NR10836). For the HAP-sensitivity test, cells were transferred using a multi-prong replicator to a minimal-medium plate, and 50 μg of HAP was applied onto the center of the plate. Plates were incubated overnight at 37 °C. For the chlorate-sensitivity test, cells were plated on LB plates containing 5 mM potassium chlorate and incubated 48 h at 37 °C under anaerobic conditions.



Table 1

*E. coli* strains used in this study.

Strain	Genotype	Source or derivation
KP7600	<i>lacI<sup>Q</sup> lacZΔM15 galK2 galT22 λ<sup>-</sup> IN(rrmD-rrnE)I</i>	Miki et al., 2008
JD26193	KP7600, but <i>moaA::mini-Tn10(lacZα-kan)χ(-)<sup>a</sup></i>	Miki et al., 2008
JD26194	KP7600, but <i>moaB::mini-Tn10(lacZα-kan)χ(+)<sup>a</sup></i>	Miki et al., 2008
JD26195	KP7600, but <i>moaB::mini-Tn10(lacZα-kan)χ(-)<sup>a</sup></i>	Miki et al., 2008
JD26196	KP7600, but <i>moaC::mini-Tn10(lacZα-kan)χ(+)<sup>a</sup></i>	Miki et al., 2008
JD26197	KP7600, but <i>moaD::mini-Tn10(lacZα-kan)χ(-)<sup>a</sup></i>	Miki et al., 2008
JD26198	KP7600, but <i>moaE::mini-Tn10(lacZα-kan)χ(+)<sup>a</sup></i>	Miki et al., 2008
BW25113	<i>lacF rnb<sub>Γ14</sub> ΔlacZ<sub>WJ16</sub> hsdR514 ΔaraBAD<sub>AH33</sub> ΔrhaBAD<sub>LD78</sub></i>	Datsenko and Wanner, 2000
KP7600-ΔB	KP7600, but <i>ΔmoaB zbi-29::Tn10</i>	This study
CAG18493	<i>zbi-29::Tn10</i>	Singer et al., 1989
NR10836	<i>ara thi Δ (p ro-lac) F'CC106</i>	Kozmin et al., 2000
NR17368	BW25113, but <i>zbi-29::Tn10</i>	BW25113 × P1/CAG18493
NR17378	NR10836, but <i>ΔmoaA zbi-29::Tn10</i>	This study
NR17379	NR10836, but <i>ΔmoaB zbi-29::Tn10</i>	This study
NR17380	NR10836, but <i>ΔmoaC zbi-29::Tn10</i>	This study
NR17381	NR10836, but <i>ΔmoaD zbi-29::Tn10</i>	This study
NR17382	NR10836, but <i>ΔmoaE zbi-29::Tn10</i>	This study
NR17383	NR10836, but <i>ΔmogA::kan</i>	Kozmin and Schaaper, 2007
NR17391	NR10836, but <i>λ(DE3) ΔguaB ΔmogA::kan</i>	Laboratory collection
NR17427	NR10836, but <i>moaB::mini-Tn10(lacZα-kan)χ(+)<sup>a</sup></i>	NR10836 × P1/JD26194
NR17428	NR10836, but <i>moaB::mini-Tn10(lacZα-kan)χ(-)<sup>a</sup></i>	NR10836 × P1/JD26195

<sup>a</sup>(+) or (-) indicate the direction of the mini-Tn10(*lacZα-kan*) on the MG1655 genome.

Table 2

HAP- and chlorate-sensitivity of wild-type, *moa*, and *mogA* strains.

Strain	Relative genotype	HAP sensitivity <sup>a</sup>		Chlorate sensitivity <sup>b</sup> KClO <sub>3</sub> (mM)		
		15	5	15	5	0.5
KP7600 derivatives:						
KP7600	wild-type	R	R	S	R	R
JD26193	<i>moaA</i> ::mini-Tn10kan	S	R	R	R	R
JD26196	<i>moaC</i> ::mini-Tn10kan	S	R	R	R	R
JD26197	<i>moaD</i> ::mini-Tn10kan	S	R	R	R	R
JD26198	<i>moaE</i> ::mini-Tn10kan	S	R	R	R	R
JD26194	<i>moaB</i> ::mini-Tn10kan	R	R	R	R	R
JD26195	<i>moaB</i> ::mini-Tn10kan	R	R	R	R	R
KP7600-ΔB	Δ <i>moaB</i> (in-frame)	R	S	S	R	R
NR10836 derivatives:						
NR10836	wild-type	R	S	S	S	I
NR17378	Δ <i>moaA</i> (in-frame)	S	R	R	R	R
NR17380	Δ <i>moaC</i> (in-frame)	S	R	R	R	R
NR17381	Δ <i>moaD</i> (in-frame)	S	R	R	R	R
NR17382	Δ <i>moaE</i> (in-frame)	S	R	R	R	R
NR17427	<i>moaB</i> ::mini-Tn10kan	R	R	S	R	R
NR17428	<i>moaB</i> ::mini-Tn10kan	R	R	S	R	R
NR17379	Δ <i>moaB</i> (in-frame)	R	S	S	S	I
NR17383	Δ <i>mogA</i> ::kan	S	R	R	R	R
NR17383-p[ <i>moaB</i> ] <sup>c</sup>	Δ <i>mogA</i> ::kan, p[ <i>moaB</i> ] <sup>c</sup>	S	R	R	R	R
NR10836-p[ <i>moaB</i> ] <sup>c</sup>	wt, p[ <i>moaB</i> ] <sup>c</sup>	R	S	S	S	I

<sup>a</sup>The sensitivity to HAP-induced killing was tested in spot-tests as described in Materials and methods. "R" indicates HAP-resistant phenotype (as "wild-type" in Fig. 1C), "S" indicates HAP-sensitive phenotype (as Δ*moaA*, *C,D,E* in Fig. 1C).

<sup>b</sup>Cells were plated on LB-chlorate plates and incubated 48 h at 37° C under anaerobic conditions (see Materials and methods). Under these conditions, chlorate-sensitive strains do not form colonies (chlorate-sensitive phenotype, "S") or form very small colonies (chlorate-inhibited phenotype, "I"), whereas chlorate-resistant strains (chlorate-resistant phenotype, "R") form colonies of the same size as on regular LB plates.

<sup>c</sup> p[*moxB*] indicates vector pBluescript II SK(+) containing the *moxB* gene (see Materials and methods). Identical results were obtained with strain NR17391 carrying plasmid pET3a-*moxB* (data not shown). All tests with plasmid-containing strains were performed in the presence of ampicillin and 0.5 mM IPTG.